Jorden David Emerson's Form 4/A amendment
AmendedNuo Therapeutics, Inc. (AURX) · filed Aug 31, 2026
- Accession no.
- 0001437749-26-029257
- Filed
- Aug 31, 2026, 10:29 AM ET
- Trade date
- Aug 27-28, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Aug 29, 2026
This filing lists 2 non-derivative transactions. Open-market purchases total $9.54K. It was filed 4 days after the trade.
This amendment replaces 0001437749-26-029236 (filed Aug 28, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jorden David EmersonCIK 0001313516 | Director, Officer (CEO/CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Common Stock | PPurchaseAcquired | +789 | $1.07 | +$844.23 | 2,062,016 | Direct | |
| Aug 28, 2026 | Common Stock | PPurchaseAcquired | +7,984 | $1.09F1 | +$8,694.58 | 2,070,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein.
Referenced by the price of 1 transaction in Table I.